GlassScriptPhysician profile
Anwer A Shaikh
NPI 1609879170
$23,720.16
in general payments reported to CMS, 2019-2025
85 companies · $3,801 in 2025
The $3,801 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $2,277 · 2021: $3,774 · 2022: $3,715 · 2023: $4,640 · 2024: $5,061 · 2025: $3,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $1,662 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,680.59 |
| Long Term Medical Supply Or Device Loan | $1,662.16 |
| Education | $159.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,187.45 | 2019-2025 | |
| Incyte Corporation | $1,102.26 | 2019-2025 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $1,054.13 | 2020-2025 | Imfinzi, Tagrisso, Calquence |
| Pfizer INC. | $1,036.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $920.26 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $877.92 | 2020-2025 | Erleada, Rybrevant, Darzalex |
| Eisai INC. | $756.09 | 2019-2025 | |
| Astellas Pharma US INC | $718.72 | 2021-2025 | Padcev, Xtandi, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $653.56 | 2020-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $628.84 | 2020-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $583.16 | 2020-2025 | Venclexta |
| Celgene Corporation | $538.71 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Rigel Pharmaceuticals, INC. | $492.93 | 2020-2024 | Tavalisse, Rezlidhia |
| Karyopharm Therapeutics INC. | $487.78 | 2020-2025 | Xpovio |
| Seagen INC. | $477.66 | 2020-2023 | Adcetris, Padcev |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $450.50 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $448.34 | 2019-2025 | Opdualag, Reblozyl, Opdivo |
| Kite Pharma, INC. | $431.60 | 2021-2025 | Yescarta |
| Amgen INC. | $430.91 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Beigene USA, INC. | $400.36 | 2020-2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $386.43 | 2020-2025 | Libtayo |
| Daiichi Sankyo INC. | $383.47 | 2020-2025 | Enhertu |
| Puma Biotechnology, INC. | $382.65 | 2019-2025 | Nerlynx |
| Bayer Healthcare Pharmaceuticals INC. | $361.67 | 2020-2025 | |
| Lilly USA, LLC | $356.56 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $318.93 | 2022-2025 | |
| Array Biopharma INC | $298.52 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Genzyme Corporation | $253.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.75 | 2020-2025 | Gilotrif |
| Blueprint Medicines Corporation | $234.99 | 2020-2025 | Ayvakit |
| Taiho Oncology, INC. | $234.07 | 2021-2024 | |
| Genentech USA, INC. | $208.00 | 2019-2025 | Venclexta, Phesgo, Gavreto |
| Emd Serono, INC. | $198.40 | 2019-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $162.42 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Foundation Medicine, INC. | $154.70 | 2021-2023 | |
| Stemline Therapeutics INC. | $151.41 | 2020-2024 | Orserdu |
| Csl Behring | $150.35 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $150.07 | 2020-2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $141.62 | 2020-2024 | Qinlock |
| Gilead Sciences, INC. | $128.92 | 2019-2025 | Trodelvy |
| Acrotech Biopharma INC. | $127.63 | 2021-2024 | Beleodaq |
| Sanofi US Services INC. | $117.83 | 2025 | |
| Alexion Pharmaceuticals, INC. | $117.75 | 2020-2024 | Ultomiris |
| Tersera Therapeutics LLC | $107.25 | 2020-2024 | Xermelo |
| Dova Pharmaceuticals | $96.19 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $94.39 | 2019-2023 | Provenge |
| Global Blood Therapeutics, INC. | $91.85 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $91.41 | 2022-2023 | Fotivda |
| Springworks Therapeutics, INC. | $87.08 | 2024-2025 | Ogsiveo |
| Epizyme, INC. | $81.22 | 2020-2022 | |
| Secura Bio, INC. | $71.15 | 2020-2021 | |
| Tempus Ai, INC | $69.88 | 2024 | |
| Geron Corporation | $68.93 | 2025 | Rytelo |
| Sumitomo Pharma America, INC. | $68.85 | 2023-2024 | Orgovyx |
| Janssen Pharmaceuticals, INC | $52.30 | 2020-2023 | Xarelto |
| Accord Healthcare, INC. | $47.64 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $47.37 | 2023-2025 | Sylvant, Enjaymo |
| Immunogen, INC. | $42.74 | 2023-2024 | Elahere, Elahere |
| Novocure INC. | $40.26 | 2021 | |
| Mirati Therapeutics, INC. | $37.80 | 2023 | Krazati |
| Eusa Pharma (US) LLC | $36.49 | 2022 | |
| Caris Mpi, INC. | $36.31 | 2025 | Mi Cancer Seek |
| Mallinckrodt Hospital Products INC. | $33.51 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $31.61 | 2023 | Firdapse |
| Syndax Pharmaceuticals, INC. | $30.85 | 2025 | |
| Adc Therapeutics America, INC. | $28.92 | 2023 | |
| Pharmaessentia USA Corporation | $27.41 | 2025 | Besremi |
| Cti Biopharma Corp. | $26.82 | 2023 | Vonjo |
| Coherus Oncology, INC. | $25.77 | 2025 | Loqtorzi |
| Amag Pharmaceuticals, INC. | $24.94 | 2021 | |
| Morphosys, US INC. | $24.93 | 2023 | Monjuvi |
| Clovis Oncology, INC. | $22.54 | 2020 | |
| Immunitybio, INC. | $22.44 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.04 | 2021 | |
| Verity Pharmaceuticals INC. | $20.49 | 2025 | Trelstar |
| Exelixis INC. | $19.60 | 2021 | |
| Tg Therapeutics, INC. | $18.38 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.57 | 2023 | Sancuso |
| Adaptive Biotechnologies Corporation | $17.38 | 2022 | |
| Ge Healthcare | $16.86 | 2021 | |
| Beone Medicines USA, INC. | $16.61 | 2025 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $14.47 | 2021 | |
| Bioxcel Therapeutics, INC. | $13.81 | 2023 | Igalmi |
| Medtronic USA, INC. | $13.23 | 2019 | |
| Tesaro, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
Kisqali $1,802Lenvima $504Imbruvica $481Jakafi $460Xpovio $418Keytruda $418Scemblix $337Padcev $247Doptelet $232Reblozyl $224Enhertu $222Adcetris $217Brukinsa $216Tavalisse $203Rezlidhia $203Jemperli $203Zejula $203Nubeqa $202Jaypirca $198Erleada $196Imfinzi $188Verzenio $181Libtayo $180Elahere $177Yescarta $174Rybrevant $158Braftovi $151Mektovi $151Tukysa $145Alunbrig $143Ninlaro $139Mekinist $136Venclexta $135Orserdu $134Ayvakit $130Pyrukynd $128Darzalex $127Xtandi $123Opdualag $119Welireg $113Elrexfio $110Onivyde $95.68Pomalyst $93.71Orgovyx $91.23Ibrance $88.74Oxbryta $84.98Epkinly $84.79Bosulif $84.63Lorbrena $83.65Fabhalta $83.60Pluvicto $82.68Gilotrif $82.26Xospata $80.98Monjuvi $80.21Stivarga $79.96Vitrakvi $79.96Lynparza $78.15Vyloy $77.12Nerlynx $75.62Piqray $73.40Talvey $71.91Tecvayli $71.91Tagrisso $69.56Rytelo $68.93Opdivo $68.37Xermelo $67.41Qinlock $66.83Ultomiris $66.59Provenge $62.87Carvykti $61.49Fotivda $61.41Calquence $60.39Promacta $59.90Beleodaq $57.89Ogsiveo $57.68Retevmo $51.07Blincyto $50.18Kyprolis $50.18Inqovi $49.55Lonsurf $49.55Fruzaqla $48.31Lutathera $48.00Camcevi $47.64Ojjaara $46.51Somatuline Depot $38.40Krazati $37.80Xalkori $37.50Sarclisa $36.70Mi Cancer Seek $36.31Firdapse $31.61Phesgo $30.10Wayrilz $29.21Rozlytrek $29.20Gavreto $29.20Tecentriq $29.20Alecensa $29.20Trodelvy $28.25Tivdak $28.22Besremi $27.41Vonjo $26.82
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwer Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.